

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 April 2020 unless otherwise stated


Semua maklumat adalah seperti pada 30 April 2020 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana Ekuiti Global (The Fund) aims to provide capital appreciation by investing in Shariah-compliant investments with exposure to the global equity markets.

Takafulink Dana Ekuiti Global (Dana) bertujuan untuk menyediakan peningkatan nilai modal dengan melabur dalam sekuriti patuh Syariah melalui pendedahan terhadap pasaran ekuiti global.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1	Aberdeen Standard Islamic World Equity Fund 100.99
2	Cash, Deposits & Others -0.99

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad (200601020898)
Inception Date / Tarikh Diterbitkan	08/07/2019
Current Fund Size / Saiz Dana Terkini	RM953,388.38
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.5% p.a.
Current NAV / NAB Terkini	RM0.99474

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana Ekuiti Global Vs. MSCI ACWI Islamic (Shariah) Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	7.83%	-5.66%	-2.17%	NA	NA	NA	-0.53%
Benchmark / Penanda Aras	9.62%	-5.53%	-5.61%	NA	NA	NA	-3.69%
Outperformance / Perbezaan Prestasi	-1.79%	-0.13%	3.44%	NA	NA	NA	3.16%

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 April 2020 unless otherwise stated

Semua maklumat adalah seperti pada 30 April 2020 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Market Review and Outlook

Global equities rebounded in April. Unprecedented monetary and fiscal stimulus around the world and a slowdown in the rate of new covid-19 infections boosted sentiment. Developed markets fared better than emerging markets. The US Federal Reserve's extensive policy easing led to the S & P 500 benchmark's fastest monthly rise since 1987. This came as the US overtook Europe to become the new epicentre of the pandemic. Nevertheless, some US states and certain European governments cautiously rolled back social-distancing measures and reopened some businesses.

In a glimpse of the potential global economic impact of the virus, China's gross domestic product (GDP) fell 6.8% year-on-year in the first quarter. Other countries, including the US, also posted dismal economic data. The International Monetary Fund estimated that global growth will shrink 3% this year. Meanwhile, oil prices fell further as the pandemic-induced drop in demand dwarfed the largest coordinated output cut in history by OPEC and its allies. The US crude West Texas Intermediate benchmark turned negative briefly as storage capacity there dwindled.

In corporate news, Swiss drugmaker Roche's first-quarter sales were higher than forecast, as global supply chains for medicines and tests remained intact in spite of the pandemic. It aimed to launch a covid-19 antibody test in May, while Actemra, an arthritis drug, is also being trialled as a possible treatment.

Similarly, Novartis saw earnings for the same period climb as hospitals and patients stocked up on drugs during pandemic. Separately, it won European approval for its inflammation drug Cosentyx to treat a form of arthritis. Management expects growing use of this medicine to eventually push annual sales beyond US\$5 billion.

Meanwhile, Swiss food giant Nestle reported its best quarterly sales growth in nearly five years. Consumers stockpiled its products, ranging from pet food and coffee to frozen meals, ahead of lockdowns.

During the month, we introduced Spanish fashion giant Inditex, a high-quality business in the retail sector with solid financials. It has a growing sustainable line, and plans to use only sustainable fabric by 2025. We also took part in Auckland International Airport's capital raise, and topped up US consumer goods giant Procter & Gamble following share-price weakness.

Fund Review & Strategy

The Fund returned 7.83% for the month, underperforming the benchmark return of 9.62% by 1.79%. Year-to-date, the fund returned -6.81%, outperforming the benchmark return of -9.43 by 2.62%.

Tinjauan dan Gambaran Bulanan

Ekuiti global melonjak pada bulan April. Rangsangan monetari dan fiskal yang belum pernah berlaku sebelumnya di seluruh dunia serta penurunan kadar jangkitan covid-19 baru telah menggalakkan sentimen. Pencapaian pasaran maju lebih baik daripada pasaran memuncuk. Pelonggaran dasar Rizab Persekutuan AS yang ekstensif telah mendorong kenaikan bulanan penanda aras S&P 500 yang paling cepat sejak tahun 1987. Lanya berlaku apabila AS menjadi pusat baru wabak tersebut selepas Eropah. Sungguhpun demikian, sebilangan negeri di AS dan kerajaan Eropah dengan berhati-hati mengundurkan langkah penjarakan sosial dan membuka kembali sebahagian perniagaan.

Sepintas lalu impak virus ke atas ekonomi global, keluaran dalam negara kasar (KDNK) China turun 6.8% tahun ke tahun pada suku pertama. Negara-negara lain, termasuk AS, turut mencatatkan data ekonomi yang suram. Dana Kewangan Antarabangsa (IMF) menganggarkan bahawa pertumbuhan global akan menyusut 3% tahun ini. Sementara itu, harga minyak semakin turun setelah permintaan merosot kerana cetusan pandemik lalu mengasak OPEC dan rakan sekutunya mengurangkan output yang diselaraskan, terbesar dalam sejarah. Penanda aras minyak mentah AS, West Texas Intermediate berubah negatif buat seketika apabila kapasiti penyimpanan di sana semakin berkurangan.

Sorotan berita korporat, jualan suku pertama pembuat ubat-ubatan dari Switzerland, Roche lebih tinggi daripada yang diunjurkan, berikutan rantaian bekalan global ubat-ubatan dan ujian tetap utuh meskipun dilanda pandemik. Ia mensasarkan untuk melancarkan ujian antibodi covid-19 pada bulan Mei, sementara Actemra sejenis ubat arthritis, turut menjalani percubaan sebagai kemungkinan rawatan.

Begitu juga, Novartis mencatat peningkatan perolehan dalam tempoh yang sama setelah hospital dan pesakit menambah penggunaan ubat-ubatan semasa pandemik. Secara berasingan, ia mendapat kebenaran dari Eropah untuk ubat keradangan Cosentyx bagi merawat arthritis. Pengurusan menjangkakan bahawa penggunaan ubat tersebut yang semakin meningkat akan mendorong jualan tahunan melebihi ASD5 billion.

Sementara itu, syarikat makanan Switzerland Nestle melaporkan pertumbuhan jualan suku tahunan terbaik dalam tempoh hampir lima tahun. Pengguna menyimpan stok produk tersebut, dari makanan haiwan kesayangan dan kopi hingga makanan sejuk beku, lebih awal dari pelaksanaan perintah kawalan pergerakan.

Pada bulan ini, kami memperkenalkan Inditex, gergasi fesyen Sepanyol, sebuah perniagaan berkualiti tinggi dengan kewangan yang kukuh dalam sektor runcit. Ia memiliki sebarisan jenama pakaian yang terus berkembang, dan merancang untuk menggunakan fabrik yang lestari sepenuhnya menjelang tahun 2025. Kami juga mengambil bahagian dalam kenaikan modal Lapangan Terbang Antarabangsa Auckland, dan menambah pegangan dalam syarikat gergasi barangan pengguna AS Procter & Gamble susulan harga saham yang rendah.

Tinjauan Dana

Dana mengembalikan 7.83% untuk bulan ini, tidak mengatasi pulangan penanda aras 9.62%, kekurangan 1.79%. Sejak awal tahun hingga kini, Dana mengembalikan -6.81%, mengatasi pulangan penanda aras -9.43%, sebanyak 3.34%.

Source / Sumber: Fund Commentary, April 2020, N/A

TAKAFULINK DANA EKUITI GLOBAL

All information as at 30 April 2020 unless otherwise stated

Semua maklumat adalah seperti pada 30 April 2020 melainkan jika dinyatakan

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL